Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China.
Conclusion: The cost-effectiveness of Rd relative to BCT for ndMM in Chinese patients is highly attractive.
PMID: 31232089 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
More News: China Health | Dexamethasone | General Medicine | Myeloma | Revlimid | Stem Cell Therapy | Stem Cells | Transplants | Velcade